CA3302765A1 - Human antibodies to bet v 1 and methods of use thereof - Google Patents

Human antibodies to bet v 1 and methods of use thereof

Info

Publication number
CA3302765A1
CA3302765A1 CA3302765A CA3302765A CA3302765A1 CA 3302765 A1 CA3302765 A1 CA 3302765A1 CA 3302765 A CA3302765 A CA 3302765A CA 3302765 A CA3302765 A CA 3302765A CA 3302765 A1 CA3302765 A1 CA 3302765A1
Authority
CA
Canada
Prior art keywords
pat
claimtext
claimnumber
bet
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3302765A
Other languages
English (en)
Inventor
Jamie M. Orengo
Andrew J. Murphy
Ashok T. Badithe
Vishal Kamat
Yashu LIU
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of CA3302765A1 publication Critical patent/CA3302765A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3302765A 2017-06-01 2018-05-31 Human antibodies to bet v 1 and methods of use thereof Pending CA3302765A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201762513872P 2017-06-01 2017-06-01
US62/513,872 2017-06-01
US201762571696P 2017-10-12 2017-10-12
US62/571,696 2017-10-12
US201862662165P 2018-04-24 2018-04-24
US62/662,165 2018-04-24
CA3063588A CA3063588A1 (en) 2017-06-01 2018-05-31 Human antibodies to bet v 1 and methods of use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3063588A Division CA3063588A1 (en) 2017-06-01 2018-05-31 Human antibodies to bet v 1 and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3302765A1 true CA3302765A1 (en) 2026-05-13

Family

ID=62705709

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3302765A Pending CA3302765A1 (en) 2017-06-01 2018-05-31 Human antibodies to bet v 1 and methods of use thereof
CA3063588A Pending CA3063588A1 (en) 2017-06-01 2018-05-31 Human antibodies to bet v 1 and methods of use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3063588A Pending CA3063588A1 (en) 2017-06-01 2018-05-31 Human antibodies to bet v 1 and methods of use thereof

Country Status (17)

Country Link
US (3) US10793624B2 (enExample)
EP (1) EP3630814A1 (enExample)
JP (3) JP6963036B2 (enExample)
KR (3) KR102329175B1 (enExample)
CN (1) CN110997713B (enExample)
AU (2) AU2018275657B2 (enExample)
BR (1) BR112019025150B1 (enExample)
CA (2) CA3302765A1 (enExample)
CL (3) CL2019003508A1 (enExample)
CO (1) CO2019013196A2 (enExample)
IL (2) IL270894B2 (enExample)
MX (2) MX2019014430A (enExample)
MY (1) MY198270A (enExample)
NZ (1) NZ759513A (enExample)
PH (1) PH12019550238A1 (enExample)
WO (1) WO2018222854A1 (enExample)
ZA (1) ZA201907513B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112545886A (zh) 2015-03-10 2021-03-26 里珍纳龙药品有限公司 无菌刺穿系统和方法
CA3055583A1 (en) 2017-05-05 2018-11-08 Regeneron Pharmaceuticals, Inc. Auto-injector
IL270894B2 (en) * 2017-06-01 2023-04-01 Regeneron Pharma Human antibodies to bet v 1 and methods of using them
US11897945B2 (en) * 2020-07-01 2024-02-13 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-Bet v 1 antibodies
CN113041271B (zh) * 2021-04-14 2022-12-27 浙江养生堂天然药物研究所有限公司 具有预防和抗过敏功效的组合物
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
US20230174632A1 (en) * 2021-12-08 2023-06-08 IgGenix, Inc. Combinations for allergy therapy
CN121241065A (zh) 2023-03-31 2025-12-30 爱尔开-阿贝优公司 适用于治疗树木花粉过敏的过敏原结合抗体
WO2024251358A1 (en) * 2023-06-07 2024-12-12 Mabylon Ag Anti-allergen antibodies and uses thereof
WO2024259313A1 (en) 2023-06-16 2024-12-19 Regeneron Pharamceuticals, Inc. Medical device packaging and related methods
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12649790B2 (en) 2023-07-03 2026-06-09 Medicovestor, Inc. Proteins that bind SP17 including fully-human anti-SP17 antibodies
US12624097B2 (en) * 2023-07-03 2026-05-12 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode anti-Sp17 antibodies and other Sp17 binding proteins
TW202529831A (zh) 2023-10-02 2025-08-01 美商再生元醫藥公司 藥物遞輸裝置安全系統
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025117894A2 (en) * 2023-11-29 2025-06-05 Medicovestor, Inc. Dimeric immunoconjugates for use in treating cancers and methods of use
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12600795B2 (en) 2023-12-26 2026-04-14 Medicovestor, Inc. Oligomeric IgG for immunotherapeutics and diagnostics
US12673991B2 (en) 2023-12-26 2026-07-07 Medicovestor, Inc. Methods of crosslinking IgG
US12121587B1 (en) 2023-12-26 2024-10-22 Medicovestor, Inc. Dimeric antibodies
WO2025165851A1 (en) 2024-01-30 2025-08-07 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-bet v 1 antibodies
WO2026125663A2 (en) * 2024-12-11 2026-06-18 Mabylon Ag Anti-allergen antibodies and uses thereof
US20260221053A1 (en) 2025-01-29 2026-07-30 Regeneron Pharmaceuticals, Inc. Drug delivery devices, safety systems, training devices, and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5411594A (en) 1992-10-27 1994-05-24 Biomay Produktions- Und Handelsgesellschaft M.B.H. Molecule fragments (peptides) of the main allergens contained in the pollen of trees of the (fagales) order
WO1994014475A1 (en) 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
EP0619323A1 (en) 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
GB0002386D0 (en) 2000-02-02 2000-03-22 Novartis Nutrition Ag Therapeutic composition
US6849259B2 (en) 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
ITMI20052517A1 (it) * 2005-12-29 2007-06-30 Lofarma Spa Varianbtio ipoallergeniche dell'allergene maggiore bet v 1 di polline di betula verrucosa
AT503297B1 (de) 2006-05-18 2007-09-15 Biomay Ag Allergen-spezifische antikörper
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
GB201002559D0 (en) 2010-02-15 2010-03-31 Circassia Ltd Birch peptides for vaccine
TWI655207B (zh) * 2013-07-30 2019-04-01 再生元醫藥公司 抗活化素ａ之抗體及其用途
EP3036543B1 (en) * 2013-08-23 2019-06-19 Regeneron Pharmaceuticals, Inc. Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit)
IL270894B2 (en) * 2017-06-01 2023-04-01 Regeneron Pharma Human antibodies to bet v 1 and methods of using them
TWI838389B (zh) 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
US11897945B2 (en) * 2020-07-01 2024-02-13 Regeneron Pharmaceuticals, Inc. Methods of treating allergy using anti-Bet v 1 antibodies

Also Published As

Publication number Publication date
EP3630814A1 (en) 2020-04-08
AU2018275657B2 (en) 2022-01-06
CL2019003508A1 (es) 2020-06-19
US20180346555A1 (en) 2018-12-06
IL270894B (en) 2022-12-01
KR102878718B1 (ko) 2025-10-31
AU2018275657A1 (en) 2019-12-19
KR20200012892A (ko) 2020-02-05
NZ759513A (en) 2022-01-28
JP2020523004A (ja) 2020-08-06
AU2022200272B2 (en) 2024-10-03
BR112019025150B1 (pt) 2022-11-08
JP7162097B2 (ja) 2022-10-27
CL2021002850A1 (es) 2022-06-24
MY198270A (en) 2023-08-18
KR102674000B1 (ko) 2024-06-11
MX2023000390A (es) 2023-02-13
JP2022174238A (ja) 2022-11-22
KR102329175B1 (ko) 2021-11-19
AU2022200272A1 (en) 2022-02-10
US10793624B2 (en) 2020-10-06
MX2019014430A (es) 2020-07-14
KR20240096746A (ko) 2024-06-26
PH12019550238A1 (en) 2020-10-19
IL298034B2 (en) 2024-05-01
IL298034B1 (en) 2024-01-01
IL270894A (en) 2020-01-30
JP2021112207A (ja) 2021-08-05
IL298034A (en) 2023-01-01
US11767358B2 (en) 2023-09-26
CN110997713A (zh) 2020-04-10
WO2018222854A1 (en) 2018-12-06
CN110997713B (zh) 2024-01-02
IL270894B2 (en) 2023-04-01
NZ782911A (en) 2025-08-29
US20240083986A1 (en) 2024-03-14
BR112019025150A2 (pt) 2020-06-23
JP7458453B2 (ja) 2024-03-29
ZA201907513B (en) 2022-04-28
CO2019013196A2 (es) 2020-01-17
CA3063588A1 (en) 2018-12-06
CL2021002851A1 (es) 2022-08-19
JP6963036B2 (ja) 2021-11-05
KR20210143327A (ko) 2021-11-26
US20210054056A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
ZA201907513B (en) Human antibodies to bet v 1 and methods of use thereof
IL281445A (en) Therapeutic nanoparticles and methods for their use
ZA201906730B (en) Anti-trem2 antibodies and methods of use thereof
PT3618863T (pt) Anticorpos anti-tigit e seus métodos de utilização
IL269077A (en) Anti-gitr antibodies and methods of use thereof
EP3525583B8 (en) Anti-c1s antibodies and methods of use thereof
SG10201912663YA (en) Anti-lag-3 antibodies and methods of use thereof
EP3625253A4 (en) ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE
EP3010938A4 (en) Fcrn-specific human antibody and composition for treatment of autoimmune diseases
EP3559042A4 (en) ANTI-LILRB3 ANTIBODIES AND METHOD OF USING THEREOF
IL274221A (en) Antibodies to ANTI-APOC3 and methods of use
EP3642231A4 (en) ANTI-VISTA ANTIBODIES AND METHODS OF USE
EP3496804A4 (en) BIOELECTRIC DEVICES AND METHODS OF USE
EP3169321A4 (en) Propolis and extracts thereof for the treatment of skin cancers and improvement of skin health
SG11202105010UA (en) Antibodies to mucin-16 and methods of use thereof
AU2018292381A1 (en) Cosmetic compositions and methods of use
IL269318A (en) Antibodies to human erythroperone and uses thereof
EP3534918A4 (en) EXOSOMS AND USES THEREOF IN BRAIN DISEASES
EP3599984A4 (en) ENDOSCOPES AND METHOD OF USE
EP3692055A4 (en) MULTIVALENT ANTIGENS FOR STIMULATING TH1 AND TH2
HK40017053A (en) Human antibodies to bet v 1 and methods of use thereof
HK40037554A (zh) 抗lrp5/6抗体和使用方法
HK40020528A (en) Antibodies to human erythroferrone and uses thereof
HK40039175A (en) Anti-tmem106b antibodies and methods of use thereof
HK40037043A (en) Anti-apoc3 antibodies and methods of use thereof

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL

Effective date: 20260224

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260224

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260224

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20260302

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260302

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260302

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20260302

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260302

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260302

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260320

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20260320

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-2-2-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20260513